This page has not been authorized, sponsored, or otherwise approved or endorsed by the companies represented herein. Each of the company logos represented herein are trademarks of Microsoft Corporation; Dow Jones & Company; Nasdaq, Inc.; Forbes Media, LLC; Investor's Business Daily, Inc.; and Morningstar, Inc.
Copyright 2025 Zacks Investment Research | 101 N Wacker Drive, Floor 15, Chicago, IL 60606
At the center of everything we do is a strong commitment to independent research and sharing its profitable discoveries with investors. This dedication to giving investors a trading advantage led to the creation of our proven Zacks Rank stock-rating system. Since 1988 it has more than doubled the S&P 500 with an average gain of +23.75% per year. These returns cover a period from January 1, 1988 through July 7, 2025. Zacks Rank stock-rating system returns are computed monthly based on the beginning of the month and end of the month Zacks Rank stock prices plus any dividends received during that particular month. A simple, equally-weighted average return of all Zacks Rank stocks is calculated to determine the monthly return. The monthly returns are then compounded to arrive at the annual return. Only Zacks Rank stocks included in Zacks hypothetical portfolios at the beginning of each month are included in the return calculations. Zacks Ranks stocks can, and often do, change throughout the month. Certain Zacks Rank stocks for which no month-end price was available, pricing information was not collected, or for certain other reasons have been excluded from these return calculations. Zacks may license the Zacks Mutual Fund rating provided herein to third parties, including but not limited to the issuer.
Visit Performance Disclosure for information about the performance numbers displayed above.
Visit www.zacksdata.com to get our data and content for your mobile app or website.
Real time prices by BATS. Delayed quotes by Sungard.
NYSE and AMEX data is at least 20 minutes delayed. NASDAQ data is at least 15 minutes delayed.
This site is protected by reCAPTCHA and the Google Privacy Policy, DMCA Policy and Terms of Service apply.
View All Zacks #1 Ranked Stocks
Zacks News
BIIB, ALKS Q3 Earnings Due on Oct 23: What's in Store?
by Zacks Equity Research
We take a look at some of the key factors of the two biotech stocks scheduled to release their third quarter results on Oct 23.
Alkermes Boasts Strong Portfolio and Impressive Pipeline
by Zacks Equity Research
Alkermes (ALKS) has a strong product portfolio, including a number of pipeline candidates with significant potential.
EBS or ALKS: Which Is the Better Value Stock Right Now?
by Zacks Equity Research
EBS vs. ALKS: Which Stock Is the Better Value Option?
FDA Sets Action Date for Recro's Pain Management Candidate
by Zacks Equity Research
The FDA has set an action date of Mar 24, 2019 for Recro's lead product candidate, intravenous (IV) meloxicam, for the management of moderate to severe pain.
VistaGen Up on Fast Track Designation to Pain Candidate
by Zacks Equity Research
VistaGen (VTGN) Fast Track designation for its pipeline candidate, AV-101, for treating neuropathic pain.
Allergan Eyes Vraylar Label Expansion, FDA Accepts sNDA
by Zacks Equity Research
FDA accepts Allergan's (AGN) sNDA for label expansion of its schizophrenia drug, Vraylar (cariprazine) to include treatment of bipolar depression.
Are Options Traders Betting on a Big Move in Alkermes (ALKS) Stock?
by Zacks Equity Research
Investors need to pay close attention to Alkermes (ALKS) stock based on the movements in the options market lately.
Alkermes Expands Study to Evaluate ALKS 4230-Keytruda Combo
by Zacks Equity Research
Alkermes expands a phase I study to evaluate its immuno-oncology candidate, ALKS 4230, in combination with Keytruda in patients with advanced solid tumors.
ANIK vs. ALKS: Which Stock Is the Better Value Option?
by Zacks Equity Research
ANIK vs. ALKS: Which Stock Is the Better Value Option?
What's in Store for Universal Health's (UHS) Q2 Earnings?
by Zacks Equity Research
Universal Health's (UHS) Q2 is likely to benefit from strong performances at its Acute Care and Behavioral Health segments.
What's in the Cards for HCA Healthcare (HCA) in Q2 Earnings?
by Zacks Equity Research
HCA Healthcare's (HCA) Q2 results are likely to be aided by a strong top line, riding on higher admissions, partially offset by increasing costs.
Is a Beat in the Cards for Centene (CNC) in Q2 Earnings?
by Zacks Equity Research
Centene's (CNC) Q2 earnings is likely to gain from higher membership and revenues from Government business.
Alkermes' Aristada Initio Approved by FDA for Schizophrenia
by Zacks Equity Research
FDA approves Alkermes' (ALKS) Aristada Initio (aripiprazole lauroxil) for the treatment of schizophrenia in adults.
Company News For Jul 3, 2018
by Zacks Equity Research
Companies in the news are: CLB, ALKS, ACXM and URI
Key FDA Events in June Investors Need to Watch Out For
by Zacks Equity Research
Investors in the healthcare industry are likely to keep a watch on upcoming PDUFA dates for key drugs in Jun 2018.
The Zacks Analyst Blog Highlights: Seagate, Grafton, Ingersoll-Rand and Alkermes
by Zacks Equity Research
The Zacks Analyst Blog Highlights: Seagate, Grafton, Ingersoll-Rand and Alkermes
4 Top Stocks to Buy As Irish Economy Gathers Steam
by Nitish Marwah
EU remains upbeat about growth prospects of the Irish economy in the years to come.
Alkermes (ALKS) Reports Wider-Than-Expected Loss in Q1
by Zacks Equity Research
Alkermes (ALKS) posts wider than expected loss in the first quarter of 2018. However, sales beat estimates.
BioMarin (BMRN) Q1 Earnings Lower Than Expected, Sales Beat
by Zacks Equity Research
BioMarin (BMRN) reported mixed first-quarter results with earnings missing estimates but sales beating the same.
Biotech Stock Roundup: ALKS Up, CLDX Down, ALXN to Acquire Wilson Therapeutics
by Zacks Equity Research
The biotech space was a witness to a series of events. while share price of several stocks moved up, a few fell substantially.
Alkermes Rallies as FDA Accepts NDA for Depression Drug
by Zacks Equity Research
Shares of Alkermes (ALKS) rose when the FDA accepted for review the new drug application for its depression candidate ALKS 5461 two weeks after it had issued a Refusal to File letter.
Company News For Apr 17, 2018
by Zacks Equity Research
Companies In The News are: JBHT,ERI,MRK,ALKS
FDA Refuses Alkermes Depression Drug Review: 4 Stocks in Focus
by Zacks Equity Research
The FDA's refusal to review Alkermes' depression candidate AKLS 5461 has brought depression disease market in focus. Here we take a look at a few companies developing products for this market.
Allergan's Vraylar Meets Endpoints in Bipolar I Phase III
by Zacks Equity Research
Allergan (AGN) along with partner Gedeon Richter posts positive top-line results from the third pivotal study, analyzing label expansion of the schizophrenia drug Vraylar to cure bipolar I depression.
Biotech Stock Roundup: EDGE Falls, ALKS Down, FDA OK's AMGN Drug Label Expansion
by Zacks Equity Research
The biotech sector grabbed headlines last week as Edge Therapeutics crashed on news of discontinuation of its phase III study while Amgen's Blincyto got FDA's nod for label expansion.